Captrust Financial Advisors Outlook Therapeutics, Inc. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.22 - $0.66 $13,200 - $39,600	-60,000 Reduced 44.07%	76,138 $29,000
Q3 2023 Nov 14, 2023	BUY	$0.2 - $1.78 $23,114 - $205,714	115,570 Added 561.89%	136,138 $29,000
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $10,200 - $18,900	10,000 Added 94.63%	20,568 $35,000
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $10,568 - $14,266	10,568 New	10,568 $11,000
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $12,200 - $20,299	10,000 New	10,000 $18,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.26B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.